Clinical trials: Neoadjuvant Treatment
HR-positive,HER2-negative Breast Cancer
Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.
This study is the first to explore the clinical study of neoadjuvant radiotherapy followed by chemotherapy combined with terriplizumab in breast cancer.
- Trial name
- NCT06705127
- Testing
- TORIPALIMAB INJECTION(JS001 ), Stereotactic Body Radiation Therapy (SBRT)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Esophageal Squamous Cell Carcinoma
PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer
The goal of this observational study is to learn about in potential operable esophageal cancer patients (cT1-2N + M0 and cT3NanyM0) receiving neoadjuvant therapy.
- Trial name
- PPIO-004-EC001 (NCT05880082)
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Breast Cancer
Surveillance Markers of Utility for Recurrence After Neoadjuvant Chemotherapy for Breast Cancer
This is a nested multicenter, prospective cohort study within the I-SPY 2 TRIAL for women undergoing neoadjuvant chemotherapy for primary breast cancer who are also undergoing definitive surgical resection and have clinical or…
- Trial name
- NCT02830282
- Testing
- Blood Collection
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Renal Failure, Chronic, Renal Transplantation
Immunoregulatory Effects of Immunoglobulin Induction Therapy in Renal Transplant Recipients
The aim of this randomized prospective study in renal transplant recipients is to investigate immunological short and long-term effects of an IVIG induction therapy.
- Trial name
- NCT00176059
- Testing
- intravenous immunoglobulins (IVIG), kidney transplantation
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University of Giessen
Prostate Cancer
GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer
RATIONALE: Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop tumor cells from growing. Thalidomide may stop the growth of prostate cancer by blocking blood flow to the tumor.
- Trial name
- NCT00400517
- Testing
- sargramostim, thalidomide, conventional surgery
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The Cleveland Clinic
Breast Cancer, Hormone Receptor-positive Breast Cancer
A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC
The 3 FDA-approved CDK4, 6 inhibitors, palbociclib, ribociclib, and abemciclib, all provided progression-free survival benefits when combined with endocrine therapy in advanced ER+/HER2- breast cancer.
- Conditions
- Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Therapy
- Trial name
- ORACLE-RIPA (NCT05766410)
- Testing
- Palbociclib, Ribociclib, Abemaciclib
- Where
- 2 sites in Taiwan
- Volunteers
- 60 people
- Sponsor
- National Taiwan University Hospital
Renal Cell Carcinoma
Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC
This is a phase II study to determine the efficacy and safety of Pembrolizumab when given in combination with Lenvatinib as treatment for patients with the advanced kidney cancer.
- Trial name
- NCT05485896
- Testing
- Pembrolizumab plus Lenvatinib
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Tianjin Medical University Second Hospital
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
The goal of this clinical trial is to evaluate the efficacy and safety of SHR-A1811 plus pertuzumab in combination with or without albumin-paclitaxel neoadjuvant therapy for early or locally advanced HER2-positive breast cancer.
- Trial name
- NCT06927180
- Testing
- SHR-A1811, Pertuzumab, Albumin-Paclitaxel
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Henan Cancer Hospital
Prostate Cancer
Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
Prostate cancer is the most common cancer in men and the second leading cause of cancer death in men. The purpose of this research study is to compare prostate cancers treated with hormone therapy versus prostate cancers treated…
- Trial name
- NCT01990196
- Testing
- degarelix, enzalutamide, trametinib
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Non-small Cell Lung Cancer
Neoadjuvant Itraconazole in Non-small Cell Lung Cancer
The purpose of this study is to determine the pharmacodynamics effects of itraconazole in early-stage non-small cell lung cancer.
- Trial name
- NCT02357836
- Testing
- Itraconazole
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Texas Southwestern Medical Center
Breast Cancer Female
Immunogenicity and Safety of DCs in Breast Cancer
This study aims to evaluate for the first time in Colombia the immunogenicity and safety of autologous DCs as enhancers of the immune response in patients with ductal breast cancer who, prior to surgical resection of the tumor…
- Trial name
- TEBICA (NCT03450044)
- Testing
- Dendritic cells
- Where
- Colombia
- Volunteers
- 15 people
- Sponsor
- Fundación Salud de los Andes
Breast Cancer, Triple Negative Breast Cancer
Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer
This is a single arm, proof of concept phase II clinical trial to evaluate the combination of Pembrolizumab and Carboplatin plus Paclitaxel in patients with localized TNBC (tumor size ≥ 10 mm and ≤ 20 mm by mammogram and/or…
- Trial name
- TELESCOPE (NCT06604858)
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 11 sites in Spain
- Volunteers
- 31 people
- Sponsor
- MedSIR
Acute Myeloid Leukemia
Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy
The purpose of this study is to assesses the benefit, safety, and pharmacokinetics (PK) of BST-236 in patients with newly-diagnosed Acute Myeloid Leukemia (AML) who are not eligible for standard induction chemotherapy due to…
- Trial name
- ELPIS (NCT03435848)
- Testing
- BST-236
- Where
- 16 sites in United States, Israel
- Volunteers
- 66 people
- Sponsor
- BioSight Ltd.
Osteosarcoma
Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma
This study is a open-lable, , single center, phase II clinical study. Target population is patients with locally resectable osteosarcoma.
- Trial name
- NCT04294511
- Testing
- Camrelizumab in Combination With Neoadjuvant Chemotherapy
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Sun Yat-sen University
NSCLC, Neoadjuvant Therapy
Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer（NSCLC）
This observational study aims to construct and validate the performance of a multimodal predictive model in forecasting the outcomes of neoadjuvant therapy in patients with NSCLC.
- Trial name
- NCT07388771
- Where
- 2 sites in China
- Volunteers
- 500 people
- Sponsor
- Qian Chu
Locally Advanced Hypopharyngeal Carcinoma
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma
The purpose of this clinical trial is to evaluate the efficacy and safety of immunotherapy combined with cetuximab and platinum neoadjuvant therapy in patients with resectable locally advanced hypopharyngeal cancer.
- Trial name
- NCT06151743
- Testing
- three cycles (toripalimab + cetuximab + platinum), Radical surgery, Radiotherapy or chemoradiotherapy
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Eye & ENT Hospital of Fudan University
HCC - Hepatocellular Carcinoma
Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin
Postoperative recurrence remains a major limitation to long-term survival in hepatocellular carcinoma (HCC). In addition, a narrow surgical margin is widely regarded as a risk factor for recurrence.
- Trial name
- NCT07518706
- Testing
- Tislelizumab, Lenvatinib
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
HER2-positive Breast Cancer
Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients
Neoadjuvant therapy in the treatment of breast cancer is not only a means of breast conserving surgery, but also a sensitive scheme for patients, in order to reduce the treatment grade, low toxicity and high efficiency.
- Trial name
- LRNacHER2 (NCT06722599)
- Where
- China
- Volunteers
- 171 people
- Sponsor
- Shu Wang
Gastric or Gastroesophageal Junction Adenocarcinoma, Propranolol
Neoadjuvant Propranolol Plus SOX and Toripalimab for Locally Advanced Gastric/GEJ Adenocarcinoma
This is a single-center, prospective, open-label, single-arm, phase Ib/II study evaluating the safety and efficacy of neoadjuvant propranolol combined with SOX chemotherapy and toripalimab in patients with resectable locally…
- Conditions
- Gastric or Gastroesophageal Junction Adenocarcinoma, Propranolol, SOX Chemotherapy, Toripalimab
- Trial name
- NCT07727993
- Testing
- propranolol, Toripalimab, Oxaliplatin
- Volunteers
- 49 people
- Sponsor
- Ting Liu
Pancreatic Cancer, Neoadjuvant Chemoradiotherapy
Oral Immunonutrition Therapy to Reduce Acute Toxicity After Neoadjuvant Chemoradiotherapy Pancreatic Cancer Patients
A prospective, single-arm clinical trial is conducted to investigate the role of oral immunonutrion in reducing acute toxicity after neoadjuvant chemoradiotherapy among pancreatic cancer patients.
- Conditions
- Pancreatic Cancer, Neoadjuvant Chemoradiotherapy, Immunonutrition
- Trial name
- NCT06736678
- Testing
- Oral Immunonutrition
- Where
- 2 sites in China
- Volunteers
- 98 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.